CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net income	$ 75,364	$ 110,463
Adjustments to reconcile net income to net cash provided by operations:
Stock-based compensation	63,732	44,558
Accretion of marketable securities	(4,010)	(8,747)
Depreciation and amortization	860	514
Deferred income taxes	(22,355)	(36,333)
Non-cash amortization of right-of-use asset	548	362
Changes in operating assets and liabilities:
Trade receivables	(15,653)	(18,594)
Insurance recovery receivable related to Melucci litigation	0	14,000
Inventory	(7,964)	383
Prepaid expenses and other current assets	(15,693)	8,462
Other assets	(1,439)	(432)
Accounts payable	19,070	1,086
Accrued research and development expenses	(5,546)	6,406
Accrued and other liabilities	17,164	27,531
Accrued Settlement related to Melucci litigation	0	(14,000)
Long-term accrued income taxes	48	2,540
Operating lease liability	(578)	38
Net cash provided by operating activities	103,548	138,237
Cash flows from investing activities:
Purchases of property and equipment	(161)	(2,051)
Proceeds from sales and maturities of marketable securities	257,536	332,545
Purchases of marketable securities	(175,774)	(443,738)
Net cash provided by (used in) investing activities	81,601	(113,244)
Cash flows from financing activities:
Proceeds from stock option exercises, net of issuance costs	13,008	3,268
Proceeds from purchases under the Employee Stock Purchase Program	7,160	3,927
Repurchases of common stock in connection with Stock Repurchase Program	(172,915)	(15,664)
Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants	(36,403)	(15,316)
Net cash used in financing activities	(189,150)	(23,785)
Net effect of exchange rate changes on cash and cash equivalents	1,474	530
Net (decrease) increase in cash and cash equivalents	(2,527)	1,738
Cash and cash equivalents, at beginning of period	127,665	135,551
Cash and cash equivalents, at end of period	125,138	137,289
Supplemental disclosure:
Exercise cost of shares repurchased for net settlement of cashless option exercises	$ 17,799	$ 14,184